| WHY DOE S A AFP NOT ENDOR S E AHA / ACC 2 017 ?
While admitting that AHA/ACC 2017 has several positives including highlighting the importance of accurate assessment of blood pressure, discussing the importance of healthy lifestyle choices to minimize hypertension risk, AAFP pointed out six reasons (Table 1) to not endorse the AHA/ACC 2017. 4 
| OVERD IAG NOS IS IN CLINI C AL PR AC TI CE G U IDELINE S
Narrowly defined overdiagnosis, for example, in cancer screening, refers to diagnosing cancer that would otherwise not go on to cause symptoms or death. 6 Broadly defined overdiagnosis includes expanding the diagnostic criteria of the disease to increase the number of people diagnosed as having the disease, with subsequent treatment offered to newly diagnosed group ending up with extremely small additional benefit. In this case, even if the benefit from the treatment exceeds the harm, if the difference is extremely small, this is at most called as low-value care.
Harm and cost of the treatment are often neglected, while in some cases, harm may exceed the small benefit. Moynihan 2013 reported that in most cases of widening disease definitions in clinical practice guidelines (CPGs), rigorous assessment of potential harms of that widening was not reported, and majority of guideline panel members disclosed financial ties to pharmaceutical companies. 7 The new threshold in AHA/ACC 2017 would lead to 46 percent of the U.S. adult population being categorized as having hypertension, while using the previous threshold, that figure would be 32 percent.
Should we call this change as overdiagnosis?
| C AN WE TRUS T AHA /ACC 2 017 ?
In 2011, National Academy of Medicine ( The SPRINT trial stopped early due to benefit leading to the potential for exaggerated benefits and an underreporting of harms
Recommendation to use a tool in an unvalidated way:
The guideline recommends the use of the ASCVD Risk Assessment Tool to determine whether medications should be initiated for blood pressure control, which is not based on evidence that using the tool in this way improves outcomes 
| Management of conflict of interest
Disclosure of COIs (commercial, noncommercial, intellectual, institutional, and patient-public activities pertinent to the potential scope of the CPG) within Guideline Development Group (GDG) and appropriate exclusion measures should be taken.
Disclosure of COIs only reflects financial COIs. Intellectual COIs
were not considered, which is a major concern of this CPG and will be discussed in detail in the next section.
| Guideline development group composition
The GDG should be multidisciplinary and balanced, comprising a variety of methodological experts and clinicians, and populations ex- 
| CPG-Systematic review (SR) intersection
Systematic reviews that meet certain standards should be used.
GDG and SR team should interact regarding the scope, approach, and output of both processes.
Usually, when we develop CPGs following GRADE system, SRs are considered to be essential in developing the CPGs. In AHA/ACC 2017, which does not adopt GRADE system, the majority of the recommendations were not based on SRs. Noteworthy is the fact that harms of treating to a lower blood pressure were not assessed in the SR.
| Establishing evidence foundations for and rating strength of recommendations
For each recommendations, benefits and harms, a summary of relevant available evidence, should be provided. A rating of the level of confidence in the evidence underpinning the recommendation and a rating of the strength of the recommendation also should be provided.
| Articulation of recommendations
Recommendations should be articulated in a standardized form detailing precisely what the recommended action is, and under what circumstances it should be performed.
As mentioned previously, harms of treating to a lower blood pressure were not assessed properly. As AAFP has pointed out, while grade for the strength of evidence was included in recommendation statements, assessment of the quality of individual studies or SRs was not provided.
| INTELLEC TUAL COI , THE MA JOR CON CERN
Conflict of interest is defined as "a set of circumstances that creates a risk that professional judgment or actions regarding a primary interest will be unduly influenced by a secondary interest." 11 According to IOM 2011, GDG members should declare all potential COIs including commercial, noncommercial, intellectual, institutional, and patient-public activities pertinent to the potential scope of the CPG.
Previous reports have proven that financial COIs of GDG members are strongly related to overdiagnosis 7 and questions about the validity of the recommendations in CPGs. 12 Intellectual COIs in CPGs are defined as "academic activities that create the potential for an attachment to a specific point of view that could unduly affect an individual's judgment about a specific recommendation." 13 Example of primary intellectual COI includes "authorship of original studies, directly bearing on a recommendation" and "peer-reviewed grant funding, directly bearing on a recommendation." 14 The influence of intellectual COI on CPG is difficult to recognize, but there are several reports that intellectual COI actually adversely affect the quality of recommendations in CPGs. 15, 16 For example, authors of primary studies are more likely than methodologist to interpret the results of a meta-analysis as indicating a strong association. 17 Another study found that the specialty and intellectual COIs of the guideline authors may affect the recommendations they give for mammography screening. 18 Therefore, IOM 2011 Standards states that GDG members should not have COI, or at least members with COIs should represent not more than a minority of the GDG. And furthermore, the chair or cochairs should not be persons with COI. 8 Looking back into AHA/ACC 2017, the Chair of the SPRINT trial steering committee was commissioned as chair of the GDG, and several other members of the panel also have intellectual COIs. Given that SPRINT trial provides the basis for the recommended change in blood pressure targets, and most of the recommendations were not based on SRs, or even in the SRs, substantial weight was given to the SPRINT trial while results from other trials were minimized, the fact that SPRINT trial main author being GDG chair is a fatal problem.
| IMPLI C ATI ON FOR JAPANE S E PRIMARY C ARE PHYS I CIAN S
It is recommended for Japanese primary care physicians to continue endorsing the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 (JSH2014), which adopts a similar hypertension threshold as JNC8. As development of clinical practice guidelines in Japan is strongly influenced by the trends in USA and Europe, I would like to sound a warning to future revision of JSH2014 as well.
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